LayerBio is developing a biodegradable nanoparticle drug delivery system for sustained release of an existing FDA-approved glaucoma drug. It will be delivered through a simple office-based procedure and is expected to last a minimum of 4 to 6 months per dose. Other products being developed include a sustained-release product for cataract surgery and a novel wound dressing that releases growth factors to promote wound healing.

This company is a spinout of the 2013 project, Medication Dispensing Intraocular Lens (mdlOL) for Cataract Surgery.

LayerBio received a $200,000 grant from the Massachusetts Life Sciences Center to support process manufacturing development for its sustained release glaucoma product. Read the full press release here.